These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 9720583)

  • 1. Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism.
    Buyse G; Waldeck K; Verpoorten C; Björk H; Casaer P; Andersson KE
    J Urol; 1998 Sep; 160(3 Pt 1):892-6. PubMed ID: 9720583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin.
    Di Stasi SM; Giannantoni A; Navarra P; Capelli G; Storti L; Porena M; Stephen RL
    J Urol; 2001 Dec; 166(6):2232-6. PubMed ID: 11696741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.
    Lehtoranta K; Tainio H; Lukkari-Lax E; Hakonen T; Tammela TL
    Scand J Urol Nephrol; 2002 Feb; 36(1):18-24. PubMed ID: 12002352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida.
    Ferrara P; D'Aleo CM; Tarquini E; Salvatore S; Salvaggio E
    BJU Int; 2001 May; 87(7):674-8. PubMed ID: 11350411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study.
    Krause P; Fuhr U; Schnitker J; Albrecht U; Stein R; Rubenwolf P
    J Urol; 2013 Nov; 190(5):1791-7. PubMed ID: 23669567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics of intravesical and oral oxybutynin chloride.
    Massad CA; Kogan BA; Trigo-Rocha FE
    J Urol; 1992 Aug; 148(2 Pt 2):595-7. PubMed ID: 1640530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical application of a stable oxybutynin solution improves therapeutic compliance and acceptance in children with neurogenic bladder dysfunction.
    Buyse G; Verpoorten C; Vereecken R; Casaer P
    J Urol; 1998 Sep; 160(3 Pt 2):1084-7; discussion 1092. PubMed ID: 9719281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population.
    Palmer LS; Zebold K; Firlit CF; Kaplan WE
    J Urol; 1997 Feb; 157(2):638-40. PubMed ID: 8996387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expanded followup of intravesical oxybutynin chloride use in children with neurogenic bladder.
    Kaplinsky R; Greenfield S; Wan J; Fera M
    J Urol; 1996 Aug; 156(2 Pt 2):753-6. PubMed ID: 8683776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intravesical oxybutynin in children with meningomyelocele. Efficient treatment with few side-effects].
    Von Zweigbergk M; Nordin B; Jonsson S
    Lakartidningen; 1996 Oct; 93(41):3573-6. PubMed ID: 8965514
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
    Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD
    Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients.
    Haferkamp A; Staehler G; Gerner HJ; Dörsam J
    Spinal Cord; 2000 Apr; 38(4):250-4. PubMed ID: 10822396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can Oral Fesoterodine Be an Alternative for Intravesical Oxybutynin Instillations in Children with Neuropathic Bladder Dysfunction?
    van den Heijkant M; De Coster K; Jansen K; Bogaert G
    Urol Int; 2019; 103(2):202-210. PubMed ID: 31117096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and effects of intravesical oxybutynin on the paediatric neurogenic bladder.
    Amark P; Eksborg S; Juneskans O; Bussman G; Palm C
    Br J Urol; 1998 Dec; 82(6):859-64. PubMed ID: 9883225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic effects of intrarectal administration of oxybutynin].
    Radziszewski P; Borkowski A
    Wiad Lek; 2002; 55(11-12):691-8. PubMed ID: 12715351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children.
    Amark P; Bussman G; Eksborg S
    Eur Urol; 1998 Aug; 34(2):148-53. PubMed ID: 9693251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Population Pharmacokinetic Model of (R)- and (S-) Oxybutynin and Its Active Metabolites After Oral and Intravesical Administration to Healthy Volunteers.
    Kretschmar M; Suleiman AA; Krause P; Albrecht U; Stein R; Rubenwolf P; Fuhr U; Taubert M
    J Clin Pharmacol; 2021 Jul; 61(7):961-971. PubMed ID: 33368382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of overactive bladder with modified intravesical oxybutynin chloride.
    Saito M; Tabuchi F; Otsubo K; Miyagawa I
    Neurourol Urodyn; 2000; 19(6):683-8. PubMed ID: 11071699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury.
    Pannek J; Sommerfeld HJ; Bötel U; Senge T
    Urology; 2000 Mar; 55(3):358-62. PubMed ID: 10699610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens.
    Di Stasi SM; Giannantoni A; Vespasiani G; Navarra P; Capelli G; Massoud R; Stephen RL
    J Urol; 2001 Feb; 165(2):491-8. PubMed ID: 11176403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.